CD86 and neoplasm: After demonstrating in vivo efficacy of our CAR/CCR construct in the treatment of CD19/CD80/CD86-positive tumors, we next raised the question whether second-line treatment with CAR (2nd Gen) or CAR/CCR T cells can increase the survival of tumor-relapsed mice after CAR T cell treatment.